1. Ganewa da kuma maganin farko na ciwon huhu
An gano majiyyaci Lu tare da adenocarcinoma na huhu da ƙwayar lymph node a ranar 26 ga Agusta, 2005. An yi amfani da ƙananan lobectomy na hagu a ranar 22 ga Satumba, 2005. An yi amfani da Carboplatin tare da taxotere sau 4 bayan tiyata. A ranar 3 ga Agusta, 2007, saboda zubar da jini, an tabbatar da ganewar asali na maimaituwa, kuma an bi da ita tare da Tarceva (yawan zagayowar ba a sani ba). A ranar 8 ga Janairu, 2008, an sami ci gaban ciwon daji akan sake duban, sa'an nan kuma an dakatar da maganin Tarceva kuma an fara maganin Libita na zagaye 16. A lokaci guda, an gano metastasis na hip vertebral kuma an yi zagaye na 4 na Zetai.
2. A karo na farko don shiga cikin gwaji na asibiti, yanayin yana ƙarƙashin iko.
A cikin watan Yulin 2010, Mista Lu ya sake nazarin babban yanki na metastasis na kwakwalwa kuma ya sami wasu ƙananan raunuka a cikin kwakwalwa. Ya kuma gwada tabbatacce ga EML4-ALK fusion gene a Jami'ar Chicago School of Medicine. Daga nan ne aka yi amfani da dukkan maganin radiation na kwakwalwa don sarrafa raunuka, kuma an fara kashi na biyu na gwajin maganin crizotinib a asibitin Jami'ar St. Louis. A lokacin jiyya, an kula da yanayin sosai, amma sake dubawa a watan Mayu 2012 ya gano cewa ciwon daji ya ɗan ɗan ci gaba, kuma tumo ana zargin yana da juriya ga crizotinib. Ya dakatar da crizotinib a ranar 18 ga Yuli, 2012.
3. A gwaji na biyu na asibiti, ciwon daji ya ɓace a fili.
A ranar 6 ga Agusta, 2012, Mista Lu ya shiga cikin maganin AP26113 gwajin gwaji at Denver Hospital. In October, the PET examination showed that the tumor disappeared and the ƙari a cikin kwakwalwa decreased and became large.
4. Gano maye gurbi da ba kasafai ba kuma sa ido don shiga cikin sabbin gwaji na asibiti
Sake jarrabawa a cikin Yuli 2014, PET gaba ɗaya ya nuna: Raunin ƙwaƙwalwa ya kasance a tsaye, kuma ƙirjin yana da ci gaba a fili. A ranar 12 ga Mayu, 2014, an yi abin da ake zargi da cutar anti-AP26113 lymph (sel 3, mafi girma 1.1 cm) layin salula na al'ada a Babban Asibitin Massachusetts kuma ya ci gaba da ɗaukar AP26113.
In August 2014, the doctor called and found that Mr. Lu’s new tumor tissue sequencing detected rare or unseen mutations. This mutation was only reported in ALK-positive children’s neuroblastoma and inflammatory myofibroblastoma. Previous research reports and medical evidence have shown that crizotinib cannot cope with the resistant neuroblastoma caused by this mutation. New genetic test results indicate that Mr. Lu may need to find new drugs for treatment.
A ranar 8 ga Disamba, 2014, bayan bincike da shawarar likita, an amince da Mr. Lu don ƙara yawan adadin AP26113 kuma ya canza shi zuwa 240 MG kowace rana, don haka shirin maye gurbin miyagun ƙwayoyi ya jinkirta na ɗan lokaci. Bayan lura da ingancin, ya yanke shawarar ko zai canza miyagun ƙwayoyi kuma ya shiga cikin wasu gwaje-gwaje na asibiti. Mai haƙuri ya koya ta hanyar asibiti cewa NIVOLUMAB monoclonal antibody immunotherapy Gwajin magani na zamani na 3/4 yana daukar majinyata cutar kansar huhu a babban sikelin, kuma Mista Lu yana da cikakken kwarin gwiwa game da rigakafin cutar kansa na gaba.
